<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03445195</url>
  </required_header>
  <id_info>
    <org_study_id>CS2514-2017-0003</org_study_id>
    <nct_id>NCT03445195</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Entasis Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Entasis Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a double-blind, randomized, placebo-controlled study to evaluate the safety and
      efficacy of IV ETX2514SUL in patients with complicated urinary tract infections (cUTIs) who
      are otherwise relatively healthy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a double-blind, randomized, placebo-controlled study to evaluate the safety and
      efficacy of IV ETX2514SUL in patients with cUTIs who are otherwise relatively healthy.
      Patients with Acute Pyelonephritis may also be enrolled. Approximately 80 patients will be
      randomized to receive either 1 g ETX2514/1 g sulbactam IV or matching placebo every 6 hours
      (q6h). All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is a double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of IV ETX2514SUL in patients with cUTIs.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite assessment of Treatment-emergent adverse event (TEAEs) and changes from patient baseline.</measure>
    <time_frame>From baseline through day 21</time_frame>
    <description>Analysis of the safety profile is a composite assessment of Treatment-emergent adverse event (TEAEs) and changes from patient baseline. A TEAE is defined as an adverse event occurring on or after the administration of the first dose of study drug.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Complicated Urinary Tract Infection</condition>
  <condition>Acute Pyelonephritis</condition>
  <arm_group>
    <arm_group_label>Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Imipenem/Cilastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulbactam-ETX2514</intervention_name>
    <description>The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.</description>
    <arm_group_label>Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin</arm_group_label>
    <other_name>ETX2514SUL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching 1g IV solution.</description>
    <arm_group_label>Placebo + Imipenem/Cilastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem-cilastatin</intervention_name>
    <description>All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.</description>
    <arm_group_label>Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin</arm_group_label>
    <arm_group_label>Placebo + Imipenem/Cilastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A signed informed consent form (ICF). If a study patient is unable to provide informed
             consent due to their medical condition, the patient's legally authorized
             representative may consent on behalf of the study patient as permitted by local law
             and institutional Standard Operating Procedures.

          -  Male or female, 18 to 90 years of age, inclusive.

          -  Expectation, in the judgment of the Investigator, that the patient's cUTI would
             require initial hospitalization and treatment with IV antibiotics.

          -  Documented or suspected cUTI or AP.

        Exclusion Criteria:

          -  Gross hematuria requiring intervention other than administration of study drug or
             removal or exchange of a urinary catheter.

          -  Known non-renal source of infection such as endocarditis, osteomyelitis, abscess,
             meningitis, or pneumonia diagnosed within 7 days prior to randomization that would
             interfere with evaluation of response to the study antibiotics.

          -  Patient requires continuing treatment with probenecid, methotrexate, ganciclovir,
             valproic acid, or divalproex sodium during the study.

          -  Receipt of a single dose of a long-acting, potentially-effective systemic antibiotic
             with activity against Gram-negative uropathogens for more than 24 hours within the
             72-hour window prior to randomization.

          -  Requirement at time of randomization for any reason for additional systemic
             antimicrobial therapy (including antibacterial, antimycobacterial, or antifungal
             therapy) other than study drug, with the exception of a single oral dose of any
             antifungal treatment for vaginal candidiasis.

          -  Likely to require the use of an antibiotic for cUTI or AP prophylaxis during the
             patient's participation in the study [from randomization through the Late Follow-up
             (LFU) Visit].

          -  Any patients previously randomized in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anibal Calmaggi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medpace, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medpace Clinical Safety</last_name>
    <phone>+1-513-579-9911</phone>
    <phone_ext>3</phone_ext>
    <email>medpace-safetynotification@medpace.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universeity Multiprofile Hospital for Active Teatment</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krassimir Yanev, MD</last_name>
      <phone>00359 8886 6327</phone>
      <email>dr_kyanev@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Vanya Ivanova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Teatment-Clinic of Nephrology</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Bogov</last_name>
      <phone>00359 2923 0263</phone>
      <email>bbogov@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Zhana Nikolova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Teatment (MHAT) and Emergency Medicine - Pirogov</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karayankova, Miroslava</last_name>
      <phone>+359 892226016</phone>
      <email>m.karayankova@rdservices.org</email>
    </contact>
    <investigator>
      <last_name>Mariyanovski, Valeri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Teatment (MHAT) and Emergency Medicine - Doverie</name>
      <address>
        <city>Sofia</city>
        <zip>1632</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mihail Kolev</last_name>
      <phone>+359 888 237 539</phone>
      <email>lio_koko@abv.bg</email>
    </contact>
    <investigator>
      <last_name>Marin Georgiev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>February 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Pyelonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Sulbactam</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

